(R)-N-BOC-1,2,3,4-四氢-3-异喹啉甲醇 | 845543-81-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: (R)-N-BOC-1,2,3,4-四氢-3-异喹啉甲醇
• 英文名称: tert-butyl (R)-3-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
• 英文别名: (R)-2-Boc-1,3,4-trihydro-3-isoquinolinemethanol；tert-butyl (3R)-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate
• CAS: 845543-81-9
• 化学式: C₁₅H₂₁NO₃
• 分子量: 263.337
• InChiKey: FPIKXSHVYZIKOS-CYBMUJFWSA-N

物化性质

• 沸点：
  393.7±35.0 °C(Predicted)
• 密度：
  1.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-N-BOC-1,2,3,4-四氢-3-异喹啉甲醇 在 lithium hydroxide 、 草酰氯 、 三氟甲磺酸二丁硼 、 双氧水 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 10.84h， 生成 (2S,3S)-2-(3,5-difluorobenzyl)-3-((R)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)-3-hydroxypropanoic acid
  参考文献：
  名称：

  [EN] CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT
  [FR] INHIBITEURS BACE-1 AMINES CYCLIQUES A SUBSTITUANT BENZAMIDE

  摘要：

  公开号：

  WO2005016876A3
• 作为产物：
  描述：

  D-1,2,3,4-四氢异喹啉-3-羧酸盐酸盐 在 dimethyl sulfide borane 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 31.0h， 生成 (R)-N-BOC-1,2,3,4-四氢-3-异喹啉甲醇
  参考文献：
  名称：

  Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties

  摘要：

  CXCR4 is a seven-transmembrane receptor expressed by hematopoietic stem cells and progeny, as well as by >= 48 different cancers types. CXCL12, the only chemokine ligand of CXCR4, is secreted within the tumor microenvironment, providing sanctuary for CXCR4(+) tumor cells from immune surveillance and chemotherapeutic elimination by (1) stimulating prosurvival signaling and (2) recruiting CXCR4(+) immunosuppressive leukocytes. Additionally, distant CXCL12-rich niches attract and support CXCR4 metastatic growths. Accordingly, CXCR4 antagonists can potentially obstruct CXCR4-mediated prosurvival signaling, recondition the CXCR4+ leukocyte infiltrate from immunosuppressive to immunoreactive, and inhibit CXCR44(+) cancer cell metastasis. Current small molecule CXCR4 antagonists suffer from poor oral bioavailability and off target liabilities. Herein, we report a series of novel tetrahydroisoquinoline-containing CXCR4 antagonists designed to improve intestinal absorption and off-target profiles. Structure activity relationships regarding CXCR4 potency, intestinal permeability, metabolic stability, and cytochrome P450 inhibition are presented.

  DOI：

  10.1021/acs.jmedchem.7b01420

文献信息

• [EN] TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5 DÉRIVÉS DE TÉTRAHYDROISOQUINOLÉINE
  申请人：CTXT PTY LTD

  公开号：WO2016034673A1

  公开（公告）日：2016-03-10

  A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

  式I的化合物，其中：n为1或2；p为0或1；R1可选地为一个或多个卤素或甲基基团；R2a和R2b分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R2c和R2d分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R3a和R3b分别选自H和Me；R4为H或Me；R5为H或Me；R6a和R6b分别选自H和Me；A为(i)可选地取代的苯基；(ii)可选地取代的萘基；或(iii)可选地取代的C5-12杂环基。
• Impact of Distinct Chemical Structures for the Development of a Methamphetamine Vaccine
  作者：Amira Y. Moreno、Alexander V. Mayorov、Kim D. Janda

  DOI：10.1021/ja108807j

  日期：2011.5.4

  (+)-Methamphetamine (METH) use and addiction has grown at alarming rates over the past two decades, while no approved pharmacotherapy exists for its treatment. Immunopharmacotherapy has the potential to offer relief through producing highly specific antibodies that prevent drug penetration across the blood-brain barrier thus decreasing reinforcement of the behavior. Current immunotherapy efforts against methamphetamine have focused on a single hapten structure, namely linker attachment at the aromatic ring of the METH molecule. Hapten design is largely responsible for immune recognition, as it affects presentation of the target antigen and thus the quality of the response. In the current paper we report the systematic generation of a series of haptens designed to target the most stable conformations of methamphetamine as determined by molecular modeling. On the basis of our previous studies with nicotine, we show that introduction of strategic molecular constraint is able to maximize immune recognition of the target structure as evidenced by higher antibody affinity. Vaccination of GIX(+) mice with six unique METH immunoconjugates resulted in high antibody titers for three particularly promising formulations (45-108 mu g/mL, after the second immunization) and high affinity (82, 130, and 169 nM for ME2, MH6, and MH7 hapten-based vaccines, respectively). These findings represent a unique approach to the design of new vaccines against methamphetamine abuse.

  （+）-甲基苯丙胺（METH）的使用和成瘾在过去二十年中以惊人的速度增长，然而目前尚无批准用于治疗的药物疗法。免疫药理学有望通过产生高度特异性的抗体来提供缓解，这些抗体可以阻止药物穿透血脑屏障，从而减少行为的强化。针对甲基苯丙胺的免疫治疗研究一直集中在单一的半抗原结构上，即连接物附着在METH分子的芳香环上。半抗原设计对免疫识别至关重要，因为它影响目标抗原的呈递，从而影响免疫反应的质量。在本文中，我们报告了系统生成一系列半抗原的设计，旨在靶向甲基苯丙胺通过分子建模确定的最稳定构象。基于我们之前对尼古丁的研究，我们表明引入战略性的分子约束能够最大化对目标结构的免疫识别，这一点通过更高的抗体亲和力得到了证明。用六种独特的METH免疫偶联物对GIX(+)小鼠进行免疫接种，结果三种特别有前途的制剂在第二次免疫后产生了高抗体滴度（45-108 μg/mL），并且表现出高亲和力（ME2、MH6和MH7半抗原基疫苗的亲和力分别为82、130和169 nM）。这些发现代表了设计新型甲基苯丙胺滥用疫苗的独特方法。
• Photocatalytic Dehydroxymethylative Arylation by Synergistic Cerium and Nickel Catalysis
  作者：Yuegang Chen、Xin Wang、Xu He、Qing An、Zhiwei Zuo

  DOI：10.1021/jacs.1c00618

  日期：2021.4.7

  broad range of free alcohols and aromatic halides can be facilely employed in this transformation, representing a new paradigm for the C(sp3)–C(sp2) bond construction between free alcohols and aryl halides with the extrusion of formaldehyde. Moreover, mechanistic investigations have been conducted, leading to the identification of a tribenzoate cerium(III) complex as a viable intermediate.

  在使用廉价铈和镍催化剂的温和反应条件下，现在可以将容易获得的游离醇用作选择性 C(sp 3 )–C(sp 2 ) 交叉偶联中操作简单且稳健的碳亲核试剂。在自动化高通量实验的推动下，空间位阻的苯甲酸酯配体已被确定为强大的铈配合物，使铈催化在新兴的金属光氧化还原催化中的协同合作成为可能。广泛的游离醇和芳族卤化物可以轻松地用于这种转化，代表了 C(sp 3 )–C(sp 2) 游离醇和芳基卤之间的键结构与甲醛的挤出。此外，还进行了机理研究，确定了三苯甲酸铈 (III) 配合物作为可行的中间体。
• Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors
  申请人：Thompson Lorin A.

  公开号：US20080153868A1

  公开（公告）日：2008-06-26

  There is provided a series of tetrahydroisoquinoline diaminopropane compounds of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R, R 8 and R 9 are as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供一系列Formula (I)的四氢异喹啉二氨基丙烷化合物或其立体异构体；或其药学上可接受的盐，其中R，R8和R9如本文所定义，它们的药物组合物和使用方法。这些化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地说，抑制Aβ肽的产生。本公开涉及用于治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物，如阿尔茨海默病和其他受抗淀粉样活性影响的疾病。
• [EN] CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT<br/>[FR] INHIBITEURS D'AMINES CYCLIQUES BACE-1 RENFERMANT UN SUBSTITUANT HETEROCYCLIQUE
  申请人：SCHERING CORP

  公开号：WO2005014540A1

  公开（公告）日：2005-02-17

  Disclosed are novel compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is formula (I) X is -0-, -C(R14)2- or -N(R)-; Z is -C(R14)2- or -N(R)-; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, -CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, -OR35, -N(R24)(R25) or -SR35; R41 is alkyl, cycloalkyl, -S02(alkyl), -C(O)-alkyl, -C(O)-cycloalkyl or -alkyl-NH-C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula (I). Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.

  揭示了具有以下结构的新化合物（I）或其药学上可接受的盐或溶剂，其中R1为结构（I），X为-0-，-C(R14)2-或-N(R)-；Z为-C(R14)2-或-N(R)-；t为0、1、2或3；每个R和R2独立地为H、烷基、环烷基、环烷基烷基、芳基、杂环芳基、杂环烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、烯基或炔基；每个R14为H、烷基、烯基、炔基、卤素、-CN、卤代烷基、环烷基、环烷基烷基、芳基、杂环芳基、芳基烷基、杂环芳基烷基、杂环烷基烷基、-OR35、-N(R24)(R25)或-SR35；R41为烷基、环烷基、-S02(烷基)、-C(O)-烷基、-C(O)-环烷基或-烷基-NH-C(O)CH3；其余变量如规范中所定义。还揭示了包括化合物的药物组合物（I）的制剂以及使用化合物（I）治疗认知或神经退行性疾病的方法。还揭示了包括化合物（I）的药物组合物和治疗方法，其与治疗认知或神经退行性疾病有用的其他药剂结合使用。